| Original language | English (US) |
|---|---|
| Pages (from-to) | 2650-2652.e1 |
| Journal | Clinical Gastroenterology and Hepatology |
| Volume | 20 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2022 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical Gastroenterology and Hepatology, Vol. 20, No. 11, 11.2022, p. 2650-2652.e1.
Research output: Contribution to journal › Short survey › peer-review
}
TY - JOUR
T1 - Low Prevalence of Screen-Detected Colorectal Cancer in an Average-Risk Population
T2 - The New Normal
AU - Shaukat, A.
AU - Marsh, T. L.
AU - Crockett, S. D.
AU - Syngal, S.
AU - Bresalier, R. S.
AU - Brenner, D. E.
N1 - Funding Information: Funding Funded by NCI CA864009 (DEB), NCI U24CA086368 (TLM, ZF), and support from Clinical Genomics Inc, Volition LLC, and, Eiken Chemical Company. Mack Ruffin is supported by the Hershey Company Professor and Dr. and Mrs. Forney George Fellowship. Funding Information: Conflicts of interest These authors disclose the following: Aasma Shaukat received research funding from Freenome Inc. Seth D. Crockett received research funding from Exact Sciences, Freenome Inc, and Guardant Inc. The remaining authors disclose no conflicts. Funding Information: The authors thank the following individuals from the Cancer Biomarker Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, for their input and support of the study: Paul Wagner, Matthew R. Young, and Sudhir Srivastava, and our participating centers (Supplementary Table 1) and site investigators for their valuable contributions. Early Detection Research Network Consortium (EDRN Consortium) members who are coauthors: Ziding Feng, Dale F. McLerran, Timothy R. Church, John A. Baron, Mack Ruffin, and Hermann Brenner. Conflicts of interest These authors disclose the following: Aasma Shaukat received research funding from Freenome Inc. Seth D. Crockett received research funding from Exact Sciences, Freenome Inc, and Guardant Inc. The remaining authors disclose no conflicts. Funding Funded by NCI CA864009 (DEB), NCI U24CA086368 (TLM, ZF), and support from Clinical Genomics Inc, Volition LLC, and, Eiken Chemical Company. Mack Ruffin is supported by the Hershey Company Professor and Dr. and Mrs. Forney George Fellowship.
PY - 2022/11
Y1 - 2022/11
UR - http://www.scopus.com/inward/record.url?scp=85118333780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118333780&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2021.09.013
DO - 10.1016/j.cgh.2021.09.013
M3 - Short survey
C2 - 34547437
AN - SCOPUS:85118333780
SN - 1542-3565
VL - 20
SP - 2650-2652.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 11
ER -